Cargando…

Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Delgado, Julio, Caballero-Baños, Miguel, Ortiz-Maldonado, Valentín, Castellà, Maria, Magnano, Laura, Juan, Manel, Urbano-Ispizua, Álvaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746038/ https://www.ncbi.nlm.nih.gov/pubmed/31723815 http://dx.doi.org/10.1097/HS9.0000000000000174

Ejemplares similares

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
por: Perez-Amill, Lorena, et al.
Publicado: (2020)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
por: Castella, Maria, et al.
Publicado: (2018)

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2022)

Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2022)

P1394: RITUXIMAB BASED LYMPHODEPLETION MAY INCREASE ENGRAFTMENT AND EFFICACY OF SECOND INFUSIONS OF CART19 CELLS IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2023)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
por: Gill, Saar, et al.
Publicado: (2022)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
por: Qin, Jim S., et al.
Publicado: (2020)

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
por: Chavez, Julio C, et al.
Publicado: (2013)

Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
por: Zou, Yixin, et al.
Publicado: (2018)

CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
por: Bartoló-Ibars, Ariadna, et al.
Publicado: (2021)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
por: Mancikova, Veronika, et al.
Publicado: (2020)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
por: Castella, Maria, et al.
Publicado: (2020)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
por: Bouzianas, Dimitrios, et al.
Publicado: (2023)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Natural Killer Cells: Angels and Devils for Immunotherapy
por: Martín-Antonio, Beatriz, et al.
Publicado: (2017)

Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
por: Ortiz-Maldonado, Valentín, et al.
Publicado: (2021)

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity
por: Haque, Shabirul, et al.
Publicado: (2021)

The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001
por: Trias, Esteve, et al.
Publicado: (2022)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vbkkmfidi8u1bl8f6keaccee5m